SCHEDULE 13G
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A1
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
DOV Pharmaceutical, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.0001 per Share
--------------------------------------------------------------------------------
(Title of Class of Securities)
259858108
--------------------------------------------------------------------------------
(CUSIP Number)
December 31, 2003
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/ / Rule 13d-1(c)
/X/ Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP 259858108 SCHEDULE 13G -2-
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Elan Corporation, plc
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Ireland
--------------------------------------------------------------------------------
5. Sole Voting Power
0
-----------------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 4,150,511
-----------------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 0
-----------------------------------------------------
8. Shared Dispositive Power
4,150,511
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
4,150,511
--------------------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
/ /
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
20.7%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
CUSIP 259858108 SCHEDULE 13G -3-
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Elan International Services, Ltd.
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Bermuda
--------------------------------------------------------------------------------
5. Sole Voting Power
0
-----------------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 4,150,511
-----------------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 0
-----------------------------------------------------
8. Shared Dispositive Power
4,150,511
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
4,150,511
--------------------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
/ /
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
20.7%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
CUSIP 259858108 SCHEDULE 13G -4-
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Elan Pharmaceutical Investments, Ltd.
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Bermuda
--------------------------------------------------------------------------------
5. Sole Voting Power
0
-----------------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 1,221,046
-----------------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 0
-----------------------------------------------------
8. Shared Dispositive Power
1,221,046
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,221,046
--------------------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
/ /
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
7.1%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
CO
CUSIP 259858108 SCHEDULE 13G -5-
Item 1(a). Name of Issuer:
DOV Pharmaceutical, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
433 Hackensack Avenue, Hackensack, New Jersey 07601
Item 2(a). Name of Person Filing:
This statement is filed on behalf of each of the following persons
(collectively, the "Reporting Persons")
(i) Elan Corporation, plc
(ii) Elan International Services, Ltd.
(iii) Elan Pharmaceutical Investments, Ltd.
Item 2(b). Address of Principal Business Office:
(i) Elan Corporation, plc
Lincoln House, Lincoln Place
Dublin 2, Ireland
(ii) Elan International Services, Ltd.
102 St. James Court
Flatts, Smiths FL 04
Bermuda
(iii) Elan Pharmaceutical Investments, Ltd. 102 St. James Court
Flatts, Smiths FL 04
Bermuda
Item 2(c). Citizenship:
(i) Elan Corporation, plc is an Irish public limited company
(ii) Elan International Services, Ltd. is a Bermuda exempted limited
liability company
(iii) Elan Pharmaceutical Investments, Ltd. is a Bermuda exempted limited
liability company
Item 2(d). Title of Class of Securities:
Common Stock, par value $.0001 per share (the "Shares")
Item 2(e). CUSIP Number:
259858108
Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c), check whether the person is a:
This Item 3 is not applicable
CUSIP 259858108 SCHEDULE 13G -6-
Item 4. Ownership:
Elan Corporation plc
(a) Amount beneficially owned as of February 11, 2004: 4,150,511 (1)
(b) Percent of class: 20.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 0
(ii) shared power to vote or to direct
the vote: 4,150,511 (1)
(iii) sole power to dispose or to direct
the disposition of: 0
(iv) shared power to dispose or to direct the disposition of: 4,150,511 (1)
Elan International Services, Ltd.
(a) Amount beneficially owned as of February 11, 2004: 4,150,511 (1)
(b) Percent of class: 20.7%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 0
(ii) shared power to vote or to direct
the vote: 4,150,511 (1)
(iii) sole power to dispose or to direct
the disposition of: 0
(iv) shared power to dispose or to direct the disposition of: 4,150,511 (1)
Elan Pharmaceutical Investments, Ltd.
(a) Amount beneficially owned as of February 11, 2004: 1,221,046 (1)
(b) Percent of class: 7.1%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 0
(ii) shared power to vote or to direct
the vote: 1,221,046 (1)
(iii) sole power to dispose or to direct
the disposition of: 0
(iv) shared power to dispose or to direct the disposition of: 1,221,046 (1)
CUSIP 259858108 SCHEDULE 13G -7-
----------
(1) 2,929,465 of the shares are beneficially owned directly by Elan
International Services, Ltd., a direct wholly-owned subsidiary of Elan
Corporation, plc, and 1,221,046 of the shares are beneficially owned
directly by Elan Pharmaceutical Investments Ltd., a direct
wholly-owned subsidiary of Elan International Services, Ltd.
CUSIP 259858108 SCHEDULE 13G -8-
Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control
Person:
Not Applicable
Item 8. Identification and Classification of Members of the Group:
Not Applicable
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certifications:
Not Applicable.
CUSIP 259858108 SCHEDULE 13G -9-
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: February 11, 2004
ELAN CORPORATION, PLC
By: /s/ William F. Daniel
-----------------------------------
Name: William F. Daniel
Title: Executive Vice President
and Secretary
Dated: February 11, 2004
ELAN INTERNATIONAL SERVICES, LTD.
By: /s/ Kevin Insley
-----------------------------------
Name: Kevin Insley
Title: President and Chief
Financial Officer
Dated: February 11, 2004
ELAN PHARMACEUTICAL INVESTMENTS, LTD.
By: /s/ Kevin Insley
-----------------------------------
Name: Kevin Insley
Title: President and Chief
Financial Officer
CUSIP 259858108 SCHEDULE 13G -10-
EXHIBIT INDEX
Page No.
A. Joint Filing Agreement dated February 11, 2004 by and among Elan
Corporation, plc, Elan International Services, Ltd. and Elan
Pharmaceutical Investments,
Ltd........................ .....................................11
CUSIP 259858108 SCHEDULE 13G -11-
EXHIBIT A
JOINT FILING AGREEMENT
The undersigned hereby agree that the statement on Schedule 13G with
respect to the Common Stock of DOV Pharmaceutical, Inc., dated as of February
11, 2004 is, and any amendments thereto signed by each of the undersigned shall
be, filed on behalf of each of us pursuant to and in accordance with the
provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.
Dated: February 11, 2004
ELAN CORPORATION, PLC
By: /s/ William F. Daniel
-----------------------------------
Name: William F. Daniel
Title: Executive Vice President
and Secretary
Dated: February 11, 2004
ELAN INTERNATIONAL SERVICES, LTD.
By: /s/ Kevin Insley
-----------------------------------
Name: Kevin Insley
Title: President and Chief
Financial Officer
Dated: February 11, 2004
ELAN PHARMACEUTICAL INVESTMENTS, LTD.
By: /s/ Kevin Insley
-----------------------------------
Name: Kevin Insley
Title: President and Chief
Financial Officer